Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases - Scorecard - MDSpire
Advertisement
Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases
Clinical Scorecard: Dosimetric Evaluation of Two Multileaf Collimator Systems in Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Stage IIIC Cervical Cancer with Lymph Node Metastases
At a Glance
Category
Detail
Condition
Stage IIIC Cervical Cancer with Lymph Node Metastases
Key Mechanisms
Volumetric Modulated Arc Therapy (VMAT) with Simultaneous Integrated Boost (SIB) for differential dosing.
Target Population
Patients with FIGO stage IIIC cervical cancer and complex lymph node metastases.
Care Setting
Oncology radiotherapy departments.
Key Highlights
Both MLC systems achieved clinically acceptable target coverage across all lymph node metastasis subgroups.
The α-MLC system demonstrated superior organ-at-risk sparing compared to the p-MLC system.
Dose escalation to metastatic lymph nodes improved local and regional control while minimizing normal tissue exposure.
Guideline-Based Recommendations
Diagnosis
Utilize FIGO 2018 staging for cervical cancer to guide treatment stratification.
Management
Implement SIB-VMAT for effective regional nodal control in advanced cervical cancer.
Monitoring & Follow-up
Regularly assess dosimetric parameters to ensure optimal target coverage and OAR sparing.
Risks
Be aware of potential complications such as radiation enteritis and cystitis due to dose escalation.
Patient & Prescribing Data
45 patients with FIGO stage IIIC cervical cancer undergoing SIB-VMAT.
Prescribed doses ranged from 45–50.4 Gy for PTV and 54–63 Gy for metastatic lymph nodes.
Clinical Best Practices
Select MLC systems based on their performance in OAR sparing and dose gradient control.
Ensure treatment plans are generated under clinically commissioned environments for real-world applicability.
